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Case presentation
A 32-year-old man of Finnish origin was admitted to the University of
Helsinki hospital for renal transplantation. Chronic glomerulonephritis
was diagnosed 2.5 years before admission; consequent severe hyper-
tension and edema were treated with atenolol, minoxidil, and furose-
mide with a relatively poor response. During that time, the patient also
had an episode of bacterial pleuritis that was treated with antibiotics
and finally by decortication of the right lung. Regular hemodialysis
treatment, initiated 1.5 months before admission, resulted in weight loss
from 113 kg to 79 kg. The patient was transfused six times with
leukocyte-poor blood from random donors. On admission, his urine
output was 500 mllday.
The patient underwent uneventful renal transplantation receiving a
DR-identical 3/0 mismatched kidney. The cold ischemia time was 41.5
hours. He was enrolled in a clinical trial comparing the efficacy of a
regimen consisting of azathioprine and steroids versus cyclosporine and
was randomized for treatment with cyclosporine alone. Cyclosporine
was initiated at a dose of 10 mg/kg/day and was tapered to 6 mg/kg/day
by day 18. The patient also received cimetidine, metoprolol, prazosin,
furosemide, and digoxin.
The patient's initial postoperative course was complicated by acute
tubular necrosis, presumed secondary to the long preservation time.
Urine output remained less than 100 mllday during the first week and
increased to greater than 400 mI/day only on day 10 (Fig. I). The patient
was hemodialyzed on alternate days during the first 2 weeks. He
remained afebrile. Blood leukocyte and thrombocyte levels ranged
between 6.6 and 8.1 x 109/liter, and 145 and 201 x 109/liter, respec-
tively. Slight eosinophilia was recorded on day 5.
The status of the allograft was monitored with fine-needle aspiration
biopsies every other day beginning on the fifth day after transplantation.
The first biopsy demonstrated slight lymphocytic and monocytic inflam-
mation in the graft with severe parenchymal cell changes characterized
by swelling and puffy vacuolization. Early lymphocytic-monocytic
inflammation, without the presence of activated lymphoid cell forms, is
characteristic of immunosuppression with cyclosporine alone, whereas
the swelling and puffy vacuolization of the parenchymal cells represent
the cytologic picture of acute tubular necrosis.
On day 7, an elevation of lymphoid cells was noted in the graft, and
lymphoid blast cells appeared in the inflammatory population. This
increase in inflammation, recorded on 2 consecutive days, corresponds
to the cytologic picture of acute cellular rejection. Accordingly, the
patient was treated with 2 to 3 mg/kg/day of steroids by mouth for 7
days. During this period, the inflammation subsided: blast cells disap-
peared from the aspirates and inflammatory mononuclear cells nearly
disappeared. Concomitantly, the parenchymal cell morphology gradu-
ally improved. These findings were considered consistent with success-
ful treatment of acute cellular rejection and with resolution of acute
tubular necrosis. The steroid dose was reduced to 0.8 mg/kg/day and
then gradually to 0.2 mg/kg/day; a small maintenance dose was contin-
ued. Concomitantly, the graft function improved significantly, the
serum creatinine level fell, and dialysis was discontinued on day 12.
On day 25, serum creatinine again increased. Fine-needle aspiration
biopsy demonstrated lymphocytic and monocytic inflammation with no
blast cells in the inflammatory infiltrate, On the other hand, the graft
tubular cells, and to a lesser extent vascular endothelial cells, demon-
strated clear isometric vacuolization. In immunoperoxidase staining,
the graft tubular cells contained cyclosporine (or its immunologically
cross-reactive derivatives). These findings were interpreted as repre-
senting cyclosporine nephrotoxicity. The cyclosporine dose was re-
duced from 6mg/kg/day to 2—3 mg/kg/day for 3 days and then was raised
to 5 mg/kg/day. The serum creatinine level fell again, reaching a nearly
normal level in the fifth postoperative week, The tubular cells returned
to normal in the aspiration cytology. The patient was discharged in the
fifth postoperative week. Since then, the serum creatinine has remained
at 1.7—2.8 mg/dl (150 to 250 .tmol/liter). The remainder of his course was
uneventful.
Discussion
DR. PEKKA J. HAYRY (Professor of Transplantation Surgery
and Immunology, University of Helsinki, Helsinki, Finland):
Before considering this patient in detail, let me first discuss the
technique of fine-needle aspiration biopsy (FNAB) of renal
transplants and the use of aspiration cytology in the monitoring
of the allograft.
Technical aspects
Presentation of the Forum is made possible by an educational grant
from Bayer AG/Miles Inc. This Forum was presented in Talloires,
France, in May 1988.
© 1989 by the International Society of Nephrology
Fine-needle aspiration biopsy, used in tumor diagnostics for
nearly two decades, was technically redesigned and adapted for
use in transplantation by Eeva von Willebrand and myself in the
late 1970s and early l980s [1]. The technical details of obtaining
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Fig. 1. Clinical course, immunosuppressive
medication, and aspiration cytology findings in the
patient presented here. Serum creatinine (p.mol/
liter, solid line), urine output (ml/24 hr, dashed
line), and hemodialysis treatments (HD) are
indicated in the top section. Administration of
cyclosporine (CyA, mg/kg/day) and steroids
(methy/prednisolone, MP, mg/kg/day) are shown in
the middle section. Note that the (drug dose) scale
is arbitrary. Inflammation in aspiration cytology
(solid line) and blastogenic component of
inflammation (dashed line, open circles) are given
in the bottom section as "corrected increment"
(CI) units. Parenchymal cell (PC) morphology,
where 1 indicates normal finding and 4 the
presence of necrotic cells, is also shown; "vac"
denotes cellular vacuolization.
a biopsy, processing the material, and evaluating the specimen
microscopically have been published in detail [21. In short, a
fine needle (0.8 mm in od) is inserted into the cortical region of
the graft without local anesthesia, and approximately 20 d of
cellular material is pulled by vacuum into Hepes-buffered
tissue-culture medium containing heparin and human serum
albumin. Concomitantly, a blood specimen is obtained in an-
other syringe, usually from the fingertip. Both specimens are
processed by a cytocentrifuge onto microscope slides and
usually are stained with May-Grunwald-Giemsa (MGG). For
additional information, monoclonal (or polyclonal) antibodies
directed to the inflammatory cell subsets, to various parts of the
cytoskeleton, and/or to cyclosporine or its metabolic deriva-
tives can be employed.
Microscopic evaluation. Three types of parenchymal cells
are evaluated morphologically: large distal tubular cells (either
granulated or non-granulated), small proximal tubular cells
often appearing in clumps, and vascular endothelial cells [2].
The viability of parenchymal cells is scored from ito 4, using an
arbitrary scale in which 1 indicates normal appearance and 4
stands for the presence of necrotic cells. Occasional glomeruli
may be present, but they cannot be evaluated unless sophisti-
cated methods are employed [31. Special techniques increase
the yield of glomeruli [3, 4].
One criterion evaluated by FNAB is the extent of inflamma-
tion. The major difficulty in interpreting inflammation is the
exclusion of blood contamination of the specimen. Inflamma-
tion is assessed by using the so-called "increment" method
(Table 1). A white-cell differential count is performed on both
the FNAB specimen and the blood specimen, and the blood
values are subtracted from the biopsy values [2]. Cell types in
excess (after subtraction) are considered to be present in excess
in the transplant. Two types of infot-mation support the accu-
racy of this approach. First, the degree of inflammation noted in
histologic specimens and in concomitantly obtained FNABs
correlates closely [5, 6]. In the study by Häyry et al in human
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Table 1. FNAB reporting form
Inflanunatory cells
FNAB
%
Blood
% Increment
Correction
factor
Corrected
increment
%
Lymphoblasts 2 0 2 1.0 2.0
Plasmablasts and plasma cells 4 0 4 1.0 4.0
Activated lymphocytes 4 0 4 0.5 2,0
Large granular lymphocytes 2 2 0 0.2 —
Lymphocytes (others) 20 5 15 0.1 1.5
Polymorphonuclear leukocytes
Juvenile forms
Neutrophils
Basophils
Eosinophils
0
58
0
3
0
85
1
2
—
—
—
1
0.1
0.1
0.1
0.1
—
—
—
0.1
Monoblasts 0 0 0 1.0 0
Monocytes 6 5 1 0.2 0.2
Macrophages 1 0 1 1.0 1.0
Total score (sum of corrected increments) 9.8
Parenchymal cells
No change
0
Swelling
I
Swelling &
vacuol.
2
Swelling &
vacuol. &
inclusions
3
Necrosis
4
Endothelial cells x
Tubular cells x
Parenchymal cells—lO per 100 inflammatory cells: representative specimen
CONCLUSION: Acute cellular rejection; moderate.
renal allografts [5], a correlation coefficient of 0.90 was obtained
between the total corrected increment in the FNAB versus the
degree of inflammation in a concomitantly obtained needle-
biopsy specimen, the latter being quantitated by point-scoring
from histologic sections. In a study by Gupta et a! [6], the total
corrected increment was compared to histologic rejection grade
from 0 to 4 in the dog in 101 concomitantly obtained FNAB and
needle-biopsy specimens. The coefficient of rank correlation of
inflammation was 0.73. Second, the result of perioperative
FNAB is highly compatible with the differential distribution of
inflammatory cells in subsequently removed and enzymatically
disaggregated, irreversibly rejected renal allograft specimens
(Table 2) [1]. The only exception is a somewhat lower-than-
expected number of macrophages in the FNAB specimen and a
higher-than-expected number of granulocytes in the enzymati-
cally disaggregated, explanted renal allograft. These minor
differences may be explained by the time interval between the
FNAB and transplantectomy, when the blood circulation in the
graft was grossly impaired [1].
Although useful for routine clinical use, the increment
method is theoretically flawed: it gives lower-than-actual values
in regard to the intensity of intragraft inflammation because of
the dilution of the FNAB specimen with blood. Possible alter-
natives to the subtraction approach have been considered
elsewhere [7, 8].
To emphasize the cytologic diagnostic criteria for rejection
and to de-emphasize those of nonrejection, the concept of
"corrected increment" was introduced. Participants of the
First International Workshop on FNAB in Munich, West Ger-
many, 1982, arrived by consensus at correction factors to the
different inflammatory (white) cell subtypes. Because blast cells
of T and B lineage are of paramount importance in acute cellular
rejection [9, 101, they have received a full correction factor of
lx. Because macrophages are linked with advanced, irrevers-
ible rejection [9—11], they also carry a full correction factor of
lx. The correction factors for the remaining inflammatory
(white) cell types are given in Table 1. The sum of corrected
increment values, the "total corrected increment," indicates
the intensity of inflammation.
Special stains. Further information on the pattern of inflam-
mation [12—141, on the presence of thrombocytes in the graft
[15], on the expression of major histocompatibility complex
antigens by graft parenchymal cells [16, 17], and on the local-
ization of cyclosporine in the transplant [18] can be obtained by
using appropriate (monoclonal) antibodies and either Staphylo-
coccus aureus labeling of cell-surface antigens [161 or indirect
immunoperoxidase labeling [171 in the quantitation of antibody
binding. These methods, too complicated for routine diagnostic
use, are important investigative tools and have been dealt with
in detail elsewhere [7].
Representativity and reproducibility of the FNAB. Because
inflammation in renal grafts is most pronounced in the cortical
region, FNABs must sample the cortex to be representative [1].
When a cytologic specimen is obtained, the representativity of
the biopsy is evaluated by the frequency of graft-derived
parenchymal cells in the FNAB differential. Cytologic criteria
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Table 2. Cytologic findings in the perioperative FNAB, in blood, and in the "increment," and comparison of the findings with the cytologic
characteristics of the same kidneys removed in the midst of fulminant rejection because of transplant rupture
Differential count (% = SD)
FNA Enzymatic dispersate of graft
Crude Crude
Cell type Blood FNA "Increment" dispersate "Increment"
Rejection (n = 5)
Lymphoblasts 0.9 0.7 3.0 1.2 2.0 4.2 2.9 3.3
Plasmablasts and plasma 0.8 0.8 3.8 2.2 3.0 4.4 1.6 3.6
cells
Lymphocytes 8.0 5.6 13.0 10.0 6.2 19.6 3.4 11.6
Granulocytes 82.4 8.3 46.8 10.0 —36.2 18.0 79b —66.8
Monocytes 5.6 4.3 10.6 1.5 3.0 12.4 3.5 6.8
Macrophages naa 11.2 5.9 11.4 20.0 6.3 20.0
Tissue cells na 10.4 4.8 10.4 22.6 6.0 22.6
Total 100% 100% 0% 100% 0%
a na = not applicable.b The unexpectedly large number of granulocytes in these dispersates, compared with, for example, rejecting rat kidneys, may be due to the fact
that an interval of approximately 6—8 hours of poor blood supply to the graft preceded the onset of symptoms and FNAB and the transplantectomy.
(Modified from Hayry and von Willebrand [1].)
for representativity have been established by a double biopsy
analysis independently by two groups of investigators [19, 20].
On one analysis, we obtained a correlation coefficient of 0.95 in
human renal allografts if both specimens contained at least 7
parenchymal cells per 100 inflammatory (white) cells [191. If the
representativity of either specimen fell below this level, the
correlation coefficient fell accordingly. No double nonrepresen-
tative biopsies were included. In another analysis, a correlation
coefficient higher than 0.95 was obtained in canine and human
kidney allografts if both biopsies contained at least 0.25 paren-
chymal cells per high-power field [201; correlation criteria also
were met when both biopsies were nonrepresentative, that is,
when the specimen contained only blood. Reproducibility of
double biopsies, when both specimens are representative, also
has been recorded by Vereerstraeten et al [211.
Adequate specimens usually can be obtained with little
practice, and without additional technical assistance. The sur-
geon can easily feel when the needle penetrates the muscular
layer and enters the cortical region through the kidney capsule.
Alternatively, ultrasound assistance can be used [22].
Diagnostic criteria for common post-transplant disorders
The characteristic cytologic alterations seen on FNAB during
the first few months after transplantation are displayed in Table
3 [2]. In acute tubular necrosis, the graft parenchymal cells,
particularly tubular cells, appear swollen and often vacuolized
in a characteristic "puffy" pattern. Usually no inflammation or
only a very low level of inflammation is present. Early stages of
acute cellular rejection are characterized by an increase in the
intensity of inflammation and by the appearance of lymphoid
blast cells and plasma cells in the aspirate. At the beginning of
most acute episodes of rejection, few mature macrophages are
present. When rejection proceeds and the intensity of inflam-
mation increases, however, mature mononuclear phagocytes
begin to appear in the aspirates. Mature macrophages are
characteristic in prolonged and irreversible rejection. Cyclo-
sporine toxicity is characterized by vacuolization of the graft
tubular cells and, to a lesser extent, of the vascular endothelial
cells. This "isometric vacuolization" (all vacuoles of approxi-
Table 3. Differential diagnosis of early renal transplant failure
by FNAB
FNAB Cytology Explanation
Isometric
vacuoli-
zation
and CyA
deposits
Serum Inflam- Tubular cell in the
creatinine mation morphology graft
Normal — — — Well-functioning
graft
Elevated — + + — ATN
Elevated CyA toxicity
Elevated + + + + — Rejection
Elevated + + + + + + + + + Rejection and
CyA toxicity
a J is possible that CyA administration as such induces some
(non-blastogenic) inflammation. (Modified from Häyry and von Wille-
brand (30].)
mately equal size) is nearly pathognomonic of cyclosporine
toxicity in renal transplants, and it is nearly invariably associ-
ated with deposits of cyclosporine (or its immunologically
cross-reactive byproducts) in the cell cytoplasm. Similar vacuo-
lization also is seen in histologic specimens from ordinary
needle biopsies; however, it is less prominent than in the
cytologic specimens. These deposits can be demonstrated, for
example, by the use of the appropriate antibodies and immu-
nofluorescence or immunoperoxidase stains. In a vascular
catastrophe, such as arterial thrombosis, the graft becomes
necrotic. Necrotic parenchymal cells of poorly identified type
are the characteristic features in the graft parenchymal compo-
nent.
In acute cellular rejection without cyclosporine toxicity or
acute tubular necrosis, the graft's parenchymal cells usually
appear normal at the beginning of the episode of rejection. With
prolonged rejection, their morphology gradually deteriorates.
In late and irreversible rejection, necrotic cells frequently are
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seen in FNAB specimens [2, 23]. It should be stressed that all
these changes, with the possible exception of "isometric va-
cuolization" in cyclosporine toxicity, are nonspecific. Thus the
interpretation of these parenchymal cell changes requires a
concomitant assessment of inflammation and sometimes stain-
ing of cyclosporine in cellular cytoplasm [24].
The following inflammatory cell types are adequately identi-
fied in MGG-stained cytosmears: lymphoblasts, representing
primarily T-blast cells; plasmablasts, representing primarily
B-blast cells; plasma cells; activated lymphocytes; large gran-
ular lymphocytes, representing primarily the graft-infiltrating
natural killer cells [251; small lymphocytes and early mono-
blasts; and monocytes and tissue macrophages at different
stages of maturation [7]. Granulocytes do not appear in signif-
icant numbers until late in rejection, when necrotic changes
develop in the transplant [7, 9]. The role of eosinophils is
controversial. In our experience, they are not found in excess
over the blood background [261. The possibility remains, how-
ever, that this interpretation is a visual artifact of the increment
method: at the beginning of rejection, eosinophilia invariably is
present in the recipient blood [26]. Subtraction of blood back-
ground to obtain the 'increment" thus also might subtract graft
eosinophilia. Alternatively, eosinophils might exist in degranu-
lated forms.
Another element seen in FNAB specimens is the throm-
bocyte. Thrombocytes are somewhat difficult to visualize in
ordinary MGG staining, but they can be identified by monoclo-
nal antibodies to the thrombocyte lineage [151. Indium-labeled
thrombocyte studies have demonstrated the accumulation of
thrombocytes in the allograft during all rejection episodes [27,
28]. This finding has been confirmed in FNAB specimens [15].
Moreover, FNAB analysis indicates that the entrapment of
thrombocytes is a two-stage process. "Loose" aggregates are
seen invariably over the blood background level in all reversible
acute episodes of rejection. Agglutination of thrombocytes onto
the graft endothelium occurs primarily during prolonged and
irreversible rejections.
In most acute episodes of rejection, lymphocytes and mo-
nocytes are the first inflammatory cells seen in the transplant.
Concomitantly and shortly thereafter, blast cells appear and
transplant function deteriorates. Low-grade inflammation exists
in most allografts even without evidence of clinical rejection.
Some low-grade, blast-cell-dominated episodes may pass clini-
cally unnoticed [29]. Along with intensified anti-inflammatory
treatment, the inflammatory cells usually disappear from the
graft, and normal function of the graft resumes. In irreversible
rejection, the blast cells prevail or are reduced in number.
Simultaneously, more lymphocytes and monocytes accumulate
in the graft. The finding of large numbers of tissue macrophages
is the most prominent cytologic hallmark of acute irreversible
rejection in the FNAB specimen [1, 7, 231, as it is in properly
stained histologic specimens [111.
Most early inflammatory episodes follow this pattern, with
minor deviations [29, 30]. Instead of occurring as a single
"peak," the inflammatory episode can persist for several days
or even weeks. Sometimes multiple episodes of inflammation
are observed with frequent exacerbations and remissions. On
some occasions, inflammation is seen in the transplant 2 to 3
days before graft function deteriorates. In other cases, signifi-
cant inflammation can occur within hours: a transplant that is
o 5 10 15 20 25 30 35 40 45 50
Days after transplantation
Fig. 2. Different profiles of inflammation. The shaded areas represent
the background on inflammation in well-functioning grafts + SD.
(Reproduced from Ref. 30 with permission of Excerpta Medica, Am-
sterdam.)
entirely tranquil in the morning can manifest inflammation at
noon and a fulminant inflammatory episode of rejection in the
evening (Fig. 2).
Many investigators agree that prophylactic immunosuppres-
sion can influence the cytologic pattern of inflammation. For
example, more severe (background) inflammation is observed
with cyclosporine compared with azathioprine (AZA) plus
steroids [31, 32]. With AZA and low-dose steroids, the first
episodes of inflammation occur early; most of them are blast-
cell dominated and intense [32, 331. With AZA and high-dose
steroids, the onset of inflammation is delayed, the intensity is
reduced, and fewer blast cells and macrophages are seen in the
aspirates during the first episode of rejection [32, 33].
Immunosuppression with cyclosporine but without steroids
usually is accompanied by prominent inflammation during the
first few days after transplantation. Lymphocytes and mononu-
clear phagocytes dominate; blastogenic response is minimal or
absent. The presence of large numbers of mature macrophages
is characteristic. A persistent low-grade inflammation is also
more common in cyclosporine-treated patients, especially with-
out steroids, than in patients receiving AZA plus steroids. The
incidence of intense inflammatory episodes is higher with
cyclosporine compared with regimens containing AZA plus
5,
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steroids or cyclosporine plus steroids [31, 32]. If cyclosporine is
suddenly withdrawn—for example, because of nephrotoxici-
ty—an acute blastogenic episode can occur rapidly. We inter-
pret these findings to indicate that the presence of macrophages
in the graft treated with cyclosporine without steroids is due to
a lack of an inhibitory effect of steroids. Rapid blastogenesis
after withdrawal of the drug indicates that the lymphocytes seen
in the graft are poised for rejection, and rejection proceeds
rapidly after the "brake" is released.
Correlations with renal allograft histology
Correlations of the FNAB findings with the "gold standard"
allograft histology have been made independently by several
groups of investigators. Most investigators agree that acute
blastogenic episodes of inflammation, identified on FNAB,
closely correlate with episodes of cellular rejection [34—36].
Bolton et a!, using immunoperoxidase stainings of fine-needle
aspirates and renal transplant core biopsy specimens, have
demonstrated a close phenotypic correlation between the fre-
quency of different inflammatory cell subtypes in the two types
of specimens [37]. Thus, an acute blastogenic pattern of inflam-
mation on FNAB is analogous to acute cellular rejection.
Evidence also exists that vascular rejection is manifest in
aspiration cytology as lymphocyte and mononuclear phagocyte-
dominated inflammation with no clear blastogenic component
[38, 39]. Moreover, our own experience and that of others
(Hammer C, personal communication) indicates that an in-
creased yield of activated endothelial cells with prominent
nucleoli also suggests vascular rejection. It should be empha-
sized, however, that only cellular rejection can be diagnosed
accurately by the FNAB; detection of vascular rejection is far
more difficult. Quantitation of the extent of vascular damage is
not possible by this procedure.
We and several other groups have demonstrated a close
correlation between the "isometric vacuolization" of the tubu-
lar and endothelial cells in the FNAB and of the graft tubular
cells in histologic specimens in cyclosporine toxicity [18, 40,
41]. Cyclosporine deposits can be visualized in FNAB with
proper antibodies, although the demonstration of these deposits
on tissue section is more difficult.
Correlations between FNAB and core biopsies also empha-
size the major differences between the two techniques. The
FNAB is not sufficient for a comprehensive evaluation of the
allograft. Such an evaluation can be done only by needle
biopsy, classic histology, and additional methods such as com-
bination of histology with monoclonal antibodies or DNA
probes. Thus the FNAB and the needle biopsy are not alterna-
tive diagnostic approaches.
On the other hand, the FNAB enables a very precise evalu-
ation of the intragraft inflammatory events as well as identifi-
cation of some of the parenchymal cell changes, such as tubular
cell degeneration (ATN) and vascular endothelial alterations (in
the context of vascular rejection). Also, isometric vacuolization
in the context of cyclosporine nephrotoxicity and cyclosporine
deposits in the graft tubular cells are more easily demonstrable
in the FNAB than in the needle biopsy.
Compared with needle biopsy, the advantage of FNAB is that
it allows repeated aspirations of the graft and close day-to-day
monitoring. Obtaining repeated biopsies is of the utmost impor-
tance (Fig. 2). Only this approach will reveal the dynamic
nature of the rejection process in an individual allograft [24].
For example, in the patient presented today, the characteristic
parenchymal-cell alterations in acute tubular necrosis disap-
peared when graft function improved. In acute cellular rejection
uncomplicated by acute tubular necrosis, the graft's parenchy-
ma! cells first appear normal, but their morphology deteriorates
with prolonged and irreversible rejection. In cyclosporine tox-
icity, the characteristic vacuolization and cyclosporine deposits
disappear as the drug dosage is reduced; these morphologic
changes take longer to normalize, however.
Variations in interpretation
At the Third International Workshop on Transplant Aspira-
tion Cytology in Mayrhofen in 1985, an analysis was performed
to examine the interpretation of aspiration cytology by individ-
uals at various centers [42]. Slides fulfilling the Helsinki cyto-
logic criteria for a normal finding (no inflammation), blastogenic
inflammation, cyclosporine toxicity, graft necrosis, and non-
blastogenic inflammation were circulated among the participat-
ing centers. No background information was included; that is,
the microscopists quantified the intensity of inflammation and
evaluated the parenchymal cell changes exclusively by their
own cytologic criteria.
Table 4 summarizes the results of this analysis. Nearly 80%
of all diagnoses determined by the participating centers were in
complete agreement with the Helsinki cytologic diagnosis.
Analysis of the remaining 20% with incompatible diagnoses
demonstrated that there was only a minor disagreement with
the Helsinki diagnosis in approximately two-thirds of the cases.
For example, the pathologist interpreted the specimen as "bIas-
togenic inflammation and ATN," and the specimen was classi-
fied in Helsinki as "advanced blastogenic inflammation." Thus
only 7% of the slides were classified as totally "wrong."
Fine-needle aspiration biopsy technology and related cyto-
logic methods (that is, application of monoclonal antibodies and
DNA hybridization methods to the FNAB specimens) have not
been developed to replace needle biopsy; only a needle biopsy
allows comprehensive evaluation of the graft. The great advan-
tage of FNAB is that this method makes it possible to monitor
intragraft parameters daily. In the vast majority of cases,
repeated aspiration biopsies make it possible to diagnose accu-
rately and to monitor the effect of treatment of most intra-graft
complications. If signs of early vascular rejection are recorded
in the FNAB, a needle biopsy is necessary. After the third
month, when the frequency of acute cellular rejection declines
and the frequency of vascular complications (including chronic
rejection) increases, the value of FNAB decreases and that of
needle biopsy increases. The two procedures, which yield
largely different types of information, should be used together.
Let us return for a moment to the patient who was presented
today. This patient had three of the most frequently encoun-
tered major complications of renal transplantation during the
immediate postoperative period. The immediate postoperative
course was complicated by prolonged acute tubular necrosis, a
complication anticipated because of the long preservation time
of the kidney. These clinical features were compatible with the
findings on aspiration biopsy cytology of swelling and puffy
vacuolization of graft tubular cells. Because no inflammation
was present in the graft, however, we expected the graft
function to improve with time. During acute tubular necrosis,
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Table 4. International Quality Control Workshop (1984): Rate of agreement with the Helsinki diagnosis, according to the diagnosisa
Center diagnosis"
Group
no.
Slide
no.
Helsinki diagnosis
(no. of Centers)
C:nt:rs
(%)Agree
Disagree
TotalX XX XXXPrimary Secondary
1 1 Normal (no inflammation) 16 16 100
11 Normal (no inflammation) 15 1 16 94
15 Normal (no inflammation) CsA toxicity 12 2 2 16 75
2 7 Normal (no inflammation) 1 I 1 2 5 20
16 Normal (no inflammation) 1 2 1 4 25
1 2 Blastogenic inflammation 16 16 100
12 Blastogenic inflammation 13 2 1 16 81
13 Blastogenic inflammation 16 16 100
2 6 Blastogenic inflammation 5 5 100
8 Blastogenic inflammation 5 5 100
17 Blastogenic inflammation ATN 2 2 4 50
19 Blastogenic inflammation 4 4 100
20 Blastogenic inflammation ATN 4 4 100
1 3 CsA toxicity 12 2 2 16 75
2 9 CsA toxicity ATN 2 1 2 5 40
1 4 Necrosis ATN 12 2 2 16 75
1 5 Nonblastogenic inflammation 10 2 4 16 63
14 Nonblastogenic inflammation 9 1 4 2 16 56
2 10 Nonblastogenic inflammation 2 2 1 5 40
18 Nonbiastogenic inflammation 4 4 100
a Source: Hayry P: Transplant aspiration cytology. A quality control analysis in 1984. Transplant Proc 17:2100, 1985. With permission.b Marked "agree" if entirely compatible with the primary diagnosis of Helsinki; x, minor disagreement; xx, marked disagreement; xxx, complete
disagreement.
C Abbreviations: CsA, cyclosporine; ATN, acute tubular necrosis.
the FNAB suggested that acute cellular rejection had become
superimposed. Surprisingly, given that the patient had not been
given steroids, this rejection (diagnosed only by FNAB) was
accompanied by minimal clinical signs. Particularly noteworthy
was the nearly complete absence of fever. Slight eosinophilia
indicated mononuclear phagocyte activation and secretion of
IL-l and/or IL-5. As is usual in such cases, the inflammation
was treated with increased immunosuppressive agents, in this
case, only steroids. If inflammation had proceeded with evi-
dence of further deterioration of graft parenchymal morphol-
ogy, however, we would have added anti-thymocyte globulin to
the treatment regimen, because we would have assumed that
the inflammation would be steroid resistant. In this case, the
inflammation resolved with steroid administration. At the same
time, graft function improved, presumably as the patient recov-
ered from acute tubular necrosis.
Clinically, the second elevation of serum creatinine could
have been interpreted as rejection, particularly because the
cyclosporine dosage and trough levels were not excessive.
However, aspiration cytology demonstrated no blastogenic
inflammation; instead, we found characteristic changes in graft
parenchymal cells corresponding to cyclosporine toxicity, that
is, swelling, "isometric vacuolization," and cyclosporine de-
posits. In our opinion, this finding ruled out the possibility of
rejection and confirmed a diagnosis of cyclosporine nephrotox-
icity. We reduced the cyclosporine dose, and his renal function
improved and serum creatinine reached nearly normal levels.
Aspiration cytology in the postoperative management of renal
transplant recipients
In our series of more than 10,000 biopsies, FNAB has been
associated with only one significant hemorrhage and no graft
losses. Although of little use in diagnosing chronic rejection
according to vascular and glomerular changes, FNAB can
predict vascular alterations to a certain extent by exposing
degenerative changes in endothelial cells. Such changes are an
indication for a needle biopsy. As demonstrated by Miller,
Gupta, and Belitsky, glomeruli also can be obtained by FNAB
and can be processed both for ordinary histologic examination
and for electron microscopy, provided that certain precautions
are taken [41. The specimen must be flushed from the needle
into a plastic centrifuge tube coated with gelatin, centrifuged,
and the resulting pellet must be encapsulated in a fibrin clot.
Thereafter, the clot containing the tissue material is removed
from the tube and is processed for conventional histology by
formalin fixation, paraffin embedding, sectioning, and staining
with hematoxylin and eosin. In 207 FNABs taken from 17
canine renal transplants, an average yield of 9.01 8.7 glomer-
uli were obtained per aspirate, compared with 6.6 3.8
glomeruli in 51 core biopsies from the same kidneys [4]. The
utility of such glomerular specimens in the management of
transplant patients remains unclear.
Postoperative treatment of a renal transplant recipient is not
difficult, provided that there is good initial graft function and
that methods for the monitoring of cyclosporine trough levels
are available. However, if the postoperative course is compli-
cated by prolonged acute tubular necrosis, as was our patient's,
a diagnosis of rejection and/or toxicity made from clinical signs
becomes unreliable. We believe, as do most other investigators,
that with repeated FNABs it is possible to manage this partic-
ular part of the postoperative course safely. In fact, in case of
delayed graft function we treat the complications exclusively on
the basis of the cytologic findings from FNAB.
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Compared with other Scandinavian centers in which the
frequency of never-functioning grafts was approximately 9%
[43], the contemporaneous frequency of never-functioning
grafts in Finland was 1% [441. We attribute this difference to our
liberal use of FNAB and to the prompt and appropriate treat-
ment of rejection episodes and cyclosporine toxicity during
acute tubular necrosis.
Monitoring the course of rejection and establishing the pri-
mary diagnosis are of equal importance. Thus, when the patient
responds well cytologically to intensified immunosuppression,
when parenchymal cell changes do not progress, and when
inflammation rapidly declines, aggressive treatment is no longer
necessary. On the other hand, if inflammation continues, blast
cells prevail in the aspirates, increasing numbers of macro-
phages are encountered and graft parenchymal cell morphology
deteriorates, additional immunosuppression is needed. Particu-
larly now when different antithymocyte globulins with high
standard and monoclonal antibodies (such as OKT3) are avail-
able, this approach offers an important alternative for treating
rejections that previously were considered "steroid resistant."
Aspiration biopsy allows one to titrate the cyclosporine
dosage more accurately. When the blood trough level for
cyclosporine exceeds that required for adequate immunosup-
pression, cyclosporine nephrotoxicity is relatively common.
Furthermore, tolerance of different individuals to cyclosporine
is highly variable. When ambiguity about the influence of
cyclosporine exists, FNAB becomes an alternative diagnostic
approach, which can establish cyclosporine nephrotoxicity
independent of the cyclosporine levels.
A final use for FNAB in renal transplantation is in monitoring
clinical trials. The FNAB can document many parameters
occurring inside the graft, such as the extent of graft parenchy.
mal (tubular) cell damage, the frequency of inflammatory epi-
sodes per patient, the day of onset of (first) inflammation,
duration of inflammation, and the intensity of inflammation.
With computer techniques it is possible to identify the impact of
different treatment modalities on these parameters [45]. Need-
less to say, using several parameters in addition to patient
survival and graft survival should greatly facilitate the interpre-
tation of these trials.
Questions and answers
Da. JEROME P. KASSIRER (Associate Physician-in-Chief, De-
partment of Medicine, New England Medical Center, Boston,
Massachusetts): The FNAB technique is being used widely,
and clinical decisions are being made based on the interpreta-
tion of FNAB findings. I have a sense of wonder that such
precise diagnostic information can be obtained by such a small
specimen, indeed, a specimen contaminated more or less with
blood. The question is, how precise is the cytologic diagnosis
by fine-needle biopsy of the major acute renal disorders from
which transplant patients suffer, namely, acute tubular necro-
sis, acute rejection, and cyclosporine toxicity? How do these
findings correlate with the diagnosis made on clinical grounds?
What is the "gold standard" against which the FNAB diagnosis
is based?
PROF. HAYRY: Needless to say, histology must be the gold
standard against which fine-needle aspiration biopsy is based.
DR. CHARLES VAN YPERSELE (University of Louvain Medical
School, Brussels, Belgium): As a followup to Dr. Kassirer's
question, may I ask you first what was the basis for the
diagnosis of rejection identifying day zero? Also, what are the
sensitivity and specificity of FNAB if the "gold standard" for
diagnosis is core biopsy?
PROF. HAYRY: How would you calculate the sensitivity and
specificity in this case?
DR. KASSIRER: One could calculate the sensitivity and spec-
ificity of FNAB in acute rejection, for example, by collecting a
series of proved cases of rejection. Cases of rejection might be
considered proved on the basis first of a clinical diagnosis; the
clinician believes that the patient has rejection, treats the
patient for rejection, and renal function improves. Then one
could confirm the diagnosis of rejection with a regular needle
biopsy. Using that group of patients with proved acute rejection
as a basis of comparison, the accuracy of fine-needle aspiration
biopsy could be assessed. For example, in 100 such patients
with "proved" acute rejection, in how many of those patients
would you make the correct diagnosis with fine-needle biopsy,
and in how many would you make an incorrect diagnosis? One
could carry out the same approach with cyclosporine toxicity
and all other diagnoses with which one is likely to confuse acute
rejection.
PROF. HAYRY: I do not think that anybody has ever tested the
sensitivity and specificity of FNAB towards rejection, cyclo-
sporine toxicity, or acute tubular necrosis against histologic
criteria as you suggested. However, a recent study that ap-
peared in Kidney International compared clinical diagnoses
with those from the results of FNAB. In this study, Helderman
et a! give a sensitivity and specificity of 90% or more for the
clinical diagnosis of acute allograft rejection, postoperative
renal allograft failure, cyclosporine toxicity, and normal func-
tion [46]. As you know, even histopathologists do not always
agree on what are, in fact, the histologic correlates of a given
clinical situation. Thus, dispute exists whether or not inflam-
mation, present in most al!ografts, is a marker of rejection,
whether isometric vacuolization (which is occasionally, de-
pending on the method of fixation, very difficult to evaluate in
histologic specimens) is a marker for cyclosporine toxicity, and
what are the exact histologic markers of acute tubular necrosis.
On the other hand, a number of investigators have compared
the FNAB finding with renal histology directly (that is, without
interpretations). This makes more sense, as both these methods
are morphologic methods.
Most investigators agree that an acute blastogenic pattern of
inflammation correlates with the histologic finding of acute
(blast-cell dominating) inflammation [34—36]. A blastogenic pat-
tern of inflammation in renal allografts is usually, but not
always, associated with deterioration of the graft function. On
most occasions, the inflammation disappears with intensified
administration of steroids, and graft function improves. These
changes can be monitored even more closely if serial FNABs or
needle biopsies are performed [20]. It thus is very likely that an
acute blastogenic pattern of inflammation in FNAB corre-
sponds with the blastogenic pattern of inflammation in his-
tologic sections. This pattern usually is referred to as to
"cellular rejection."
Evidence also exists that vascular rejection is visualized in
aspiration cytology as lymphocyte- and monocyte-dominated
inflammation with no clear blastogenic component [38, 39].
There is also increased shedding of endothelial cells, and
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upregulation of cellular markers of endothelial cell activation,
such as prominence of nucleoli. It should be stressed, however,
that FNAB does not permit final determination of the differen-
tial diagnosis; a core biopsy and complete histologic evaluation
for vascular rejection are necessary. Finally, there is a whole
variety of histologic combinations of these two major patterns
of "rejection." Thus, a "rejection" is not one and the same
process in all patients.
Our group [18] and others [40, 41] demonstrated a close
correlation between isometric vacuolization of the tubular
epithelial cells in the FNAB and similar changes in the graft
tubular cells in histologic specimens in the presence of clinically
proven cyclosporine toxicity: impairment of graft iunction,
little or no inflammation in renal histology, and improvement of
graft function with the reduction of cyclosporine dosage. Again,
isometric vacuolization and, even more, cyclosporine deposits
in the allograft are not uniformly demonstrated in needle
biopsies by all pathologists. The reasons can be manifold: the
use of different types of antibodies, different fixation tech-
niques, etc. There has been no way of testing the sensitivity and
specificity against histology in a way you suggested, although
most likely isometric vacuolization and cyclosporine deposits
do reflect cyclosporine nephrotoxicity, especially early acute
cyclosporine nephrotoxicity. Late changes in needle biopsies
have been described, for example, by Mihatch [47].
DR. JORDAN J. COHEN (Dean of Medicine, State University
of New York at Stony Brook, Stony Brook, New York): Given
the inability of the FNAB to diagnose recurrent disease, over
what period of time after transplantation is FNAB useful for
determining the differential diagnosis of graft failure?
PROF. HAYRY: The shorter the time between transplantation
and biopsy, the better an FNAB differentiates the in-situ
complications. During the first 3 months, the FNAB seems to
be reasonably reliable in differentiating among acute cellular
rejection, cyclosporine toxicity, and acute tubular necrosis. An
acute vasculitic pattern of early rejection cannot be comprehen-
sively evaluated by FNAB even during that time, however.
Later changes in the graft are more difficult to discern by the
FNAB. If you want me to give some sort of hallmark in this
respect, I would suggest that until the first 3 months, the FNAB
is quite reliable, at least in the hands of an experienced center.
DR. COHEN: What are the complications of FNAB?
PROF. HAYRY: There are virtually no complications of
FNAB. We perform, as do most centers, graft aspirations
approximately three times weekly. During the first 10,000
aspirations or so, we had one significant hemorrhage with
temporary clotting of the ureter. This complication resolved
spontaneously. Again, I must stress that aspiration biopsies
must be repeated to evaluate the dynamic nature of the in-situ
complications.
PROF. EBERHARD RITZ (University of Heidelberg, Heidel-
berg, Federal Republic of Germany): Pursuing the issue of
specificity that had been addressed by Professors Kassirer and
van Ypersele, I have one question. One persistent problem is
the grafted patient with viral infection, particularly cytomega-
lovirus (CMV). Does a rise of serum creatinine reflect CMV,
rejection, or a combination of both? Could you share with us
your experience on fine-needle aspriation biopsy in making
these distinctions?
PROF. HAYRY: That is a very good question and one that is
very difficult. First, CMV infection, especially primary CMV,
nearly always generates rejection in the transplant graft. At the
time of the peak incidence of CMV, patients are nearly always
at home, and they return to the hospital when they feel ill. Most
of these patients do have acute inflammation of the graft
together with an increased serum creatinine level. Whether the
activated immunocompetent (blast) cells are directed to CMV,
to donor antigens, or to both, is the question.
Demonstration of the "early" CMV antigen in the graft
and/or demonstration of viral DNA might help solve the prob-
lem, at least partially: if there is no viral DNA in the graft, if no
"early" antigen is demonstrable in the graft, and finally, if the
short-term (24-hour) culture of the FNAB specimens is negative
for CMV, the diagnosis is most likely rejection. We usually
treat these rejections with steroids or antithymocyte globulin,
although we realize the hazard. Neither FNAB nor conven-
tional histology can solve your problem at present.
PROF. L. A. VAN Es (Chief, Department of Nephrology,
Leiden University, Leiden, The Netherlands): With regard to
the role of CMV infection in the impairment of graft function, I
can report that CMV infection of cultured endothelial cells from
umbilical veins leads to a higher degree of HL-A class-I
antigens but not of class-I! antigens. This upregulation of class-I
expression was stronger than that which could be achieved with
gamma interferon (unpublished observation).
PROF. HAyRy: This may well be the case. However, the
upregulation of class-I! antigens in the graft in the context of
CMV infection, which presumably triggers the rejection, takes
place in the microvascular endothelium. Moreover, umbilical
cord venous endothelium is a highly special type of endothe-
hum.
PROF. WOLFGANG THOENES (Director, Department of
Pathology, University of Mainz, Mainz, Federal Republic of
Germany): As a pathologist, I have two questions. First, as you
know, from a tissue slice derived from a needle biopsy, we
usually diagnose only a "cellular rejection." If I am right, based
on fine-needle biopsy, you diagnose a "cellular rejection"
without and with a lymphoblastic population. Did you correlate
your fine-needle findings with biologic observations in the same
patient?
Second, in my experience the isometric vacuohization as a
sign of cyclosporine toxicity is very focally distributed in renal
tissue. How certain is the diagnosis of cyclosporine toxicity in
fine-needle biopsy using this criterion? How often did you
diagnose cyclosporine toxicity by fine-needle biopsy using the
criterion of isometric vacuohization?
PROF. HAYRY: As I said, we do not diagnose "cellular
rejection" without a blastogenic component in the inflamma-
tion. The original experience is based on animal studies [10] and
was subsequently compiled from human observations [1].
Again, I must emphasize the need for repeated biopsies. To
establish a diagnosis of acute cellular rejection, one must have
a clear blastogenic component, at least in the first specimens.
Concomitantly with intensified immunosuppression, blast cells
first disappear from the aspirate; finally, the remaining inflam-
mation disappears.
I agree that isometric vacuolization is sometimes only focally
distributed in ordinary renal histologic specimens. We have
compared needle biopsies and fine-needle biopsies in this
respect and uniformly have found that in the FNAB, isometric
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vacuolization is much more easily demonstrable than in needle
biopsy. We use isometric vacuolization as the main criterion for
cyclosporine toxicity at present. We rarely use antibodies to
substantiate a diagnosis, except for investigative purposes.
PROF. FRITZ BUHLER (Head, Hypertension Unit, University
Hospital, Base!, Switzerland): Platelet aggregates on renal
endothelial cells point to a platelet-endothelial wall interaction.
A so-far regulated mechanism may be the endothelial cell-
derived relaxation factor (EDRF). Investigators in our labora-
tory have looked at renal arteries from cyclosporine A-treated
rats. Independent of aspirin pretreatment, cyclosporine A-
treated rats showed a blunted response to acetylcholine, which
releases EDRF specifically, and less cGMP production (second
messenger of EDRF). This suggests a role for EDRF in cyclo-
sporine A-induced vasconstriction and hypertension.
PROF. HAYRY: I agree. Sporadic information also exists from
other sources that the endothelial cell-derived relaxation factor
plays a role in cyclosporine nephrotoxicity. In this respect I
refer you to recent writings of Mihatch [47].
PROF. RITz: I have a brief comment on Professor BUhler's
observation on EDRF. Hypothetically, cyclosporine A-induced
damage would be a phenomenon that could cut two edges. A
Tokyo group reported in Nature on endothelin, a substance
produced by endothelial cells [48]; this substance is the most
potent pressor agent (on a molar basis) described to date.
Consequently, the net results of endothelial cell damage, in
quantitative terms, must be quite complex.
PROF. GIUSEPPE REMUZZI (Head, Laboratory of Kidney
Diseases, Mario Negri Institute for Pharmacological Research,
Bergamo, italy): How does cyclosporine toxicity, as detected
by fine-needle aspiration biopsy (namely, isometric vacuoliza-
tion of tubular cells), correlate with blood levels of cyclo-
sporine, and how do cyclosporine deposits in the graft correlate
with blood levels of cyclosporine?
PROF. HAYRY: There is very little correlation with cyclo-
sporine toxicity either clinically or as detected by the FNAB on
one hand, and on the blood levels of cyclosporine on the other
hand, with the exception of extremely high levels.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You noted that
the rate of agreement of diagnosis among institutions is approx-
imately 80%. Have you done comparable, rigorous studies
within your institution to determine your own rate of reproduc-
ibility?
PROF. HAYRY: Let me tell you that 80% reproducibility in an
international, inter-laboratory, quality-control analysis is ex-
tremely high. The result is clearly better than, for example, the
rate of correct identification of abnormal cell types in ordinary
blood or bone marrow smears [49], or the establishment of a
correct hematologic diagnosis in less common hematologic
disorders [50], or the rate of correct histologic identification of
several types of tumors by a panel of laboratories; these include
lung carcinoma [51], carcinoma of the cervix [52], or thyroid
carcinoma [53]. Regarding our own reproducibility, we have
performed simultaneous double biopsies from a single kidney
allograft and compared the reproducibility of the count in the
two specimens. If both specimens are representative, the re-
sults are entirely concordant [19].
DR. KASSIRER: Let me extend Dr. Harrington's question:
What is the correlation between two fine-needle aspiration
biopsies simultaneously taken from a renal transplant?
PROF. HAYRY: Our correlation coefficient, if both biopsies
are representative—that is, if they contain more than 7 paren-
chymal cellsf 100 white cells—is 0.956 [19]. A similar study
performed by Belitsky et al reported a 0.95 correlation coeffi-
cient if both specimens contained at least 0.25 parenchymal
cells per high-power field [20].
DR. COHEN: Has anyone used FNAB to study the natural
history of inflammation in non-transplantation settings, for
example, in infection, autoimmunity, or allergic reactions?
PROF. HAYRY: Yes, we have tried to monitor the natural
course of diabetes by performing serial fine-needle aspiration
biopsy of the native pancreas through the stomach. The yield of
islet cells was too small to allow us to correctly evaluate the
specimens. No complications were recorded. A student of
mine, Dr. Tötterman, has performed a number of studies on
autoimmune thyroiditis in Grave's disease, Hashimoto's thy-
roiditis, de Guervain's thyroiditis, and in juvenile autoimmune
thyroiditis [54—56].
PROF. VAN Es: Several investigators have performed routine
core biopsies when clinical signs of rejection were not present.
They have often observed considerable interstitial infiltrate in
these biopsies. With frequent FNABs available, how often does
this finding occur in your experience? How often did you not
treat? Does this not pose a difficult scientific problem? Does this
represent true rejection being regulated down by suppressor
mechanisms, or does this represent a false-positive condition?
PROF. HAYRY: This phenomenon also is seen with FNAB. To
the contrary of what most clinicians believe, practically all
allografts undergo a certain level of inflammation during the first
few months postoperatively. In the FNAB, we consider "back-
ground" inflammation anything below 2.5 corrected increment
(Cl) units. This level is based on a very large computer analysis
and represents the upper 95% confidence limit. Most of these
grafts function perfectly well and, needless to say, there is no
reason for giving these patients additional immunosuppressive
drugs.
In approximately one-third of acute blastogenic inflammatory
episodes, no or only a very minor deterioration in graft function
is observed. The inflammatory episodes are usually very mild,
and we consider these "subclinical" cellular rejections. In case
initial graft function is good, we do not treat these patients
unless we find a deterioration in graft function.
Finally, we have a very high incidence of acute tubular
necrosis in our renal transplants, primarily because of long
preservation times—on the average longer than 40 hours.
Under these circumstances, we primarily treat inflammation; in
other words, if a blastogenic pattern of inflammation appears in
the graft, we treat it, as no marker of graft function is available.
This might be one reason why our frequency of never-func-
tioning grafts is less than 1%.
PROF. ROBERT A. KOENE (Head, Division of Nephrology,
University Hospital, Nijmegen, the Netherlands): You told us
that you use immunohistologic evaluation for investigational
purposes only. Hall et al showed a few years ago that an
increase in lymphoblasts together with increased DR expres-
sion on tubular cells is a highly specific and sensitive indicator
of rejection [57]. Would that technique not be a better approach
than only looking at cell morphology? This technique would
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make it unnecessary to correct for contamination of the aspi-
rates with peripheral blood.
PROF. HAYRY: Yes, this is what Bruce Hall States, and he is
correct. Hall was in fact one of the first trainees for FNAB in
our laboratory. I do not deny his observation; in fact, we
published the same observation a couple of years earlier [58,
591. We consider additional markers unnecessary on most
occasions, as our experience with plain cytology is very satis-
factory. If you wish, you can use antibodies to class-Il and also
to anti-IL-2 receptors as additional markers of acute "re-
jection"; both markers are closely linked to the acute blasto-
genic pattern of inflammation.
PROF. VAN Es: What type of antibody do you use to detect
cyclosporine in renal biopsy specimens?
PROF. HAYRY: Originally we used rabbit antiserum provided
by the Sandoz radioimmunoassay kit. It was an excellent
antibody. Later, antibody produced in sheep was not as good.
Two monoclonal antibodies are now available; one is monospe-
cific to the original cyclosporine molecule, recognizing the
whole molecule's one epitope; the other antibody recognizes
part of the molecule as one epitope and therefore cross-reacts
with several metabolites. We have not yet systematically ana-
lyzed the reliability of these two antibodies and compared the
results to both isometric vacuolization by FNAB and the
clinical situation. Unfortunately, no rabbit antibody is left in
our laboratory any longer. Von Willebrand says, however, that
these two antibodies behave in approximately similar fashion.
DR. KASSIRER: Do you have any evidence that the frequent
use of FNAB has altered the long-term outcome of patients with
renal transplants as compared with patients whose renal diag-
noses were established by other means?
PROF. HAYRY: I think you have posed a question impossible
to answer. Since 1970, our cadaveric renal transplant results
(graft survival) have improved, at the one-year checkpoint,
from 30% to approximately 90%, when we consider primary
allografts only. In 1978, when we started the use of aspiration
cytology, the results were approximately 40% to 45%. A
significant improvement has occurred during the time we used
aspiration cytology. Practically the whole treatment regimen
has been altered several times during this period, however, and
the diagnosis of infectious conditions, including CMV infection,
has greatly improved. I do not think, therefore, that there is any
way of pinpointing one or another of these management
changes as being solely responsible for the improved results.
Reprint requests to Prof. P. Hayry, Transplantation Laboratory,
University of Helsinki, Haartmaninkatu 3A, SF 00290 Helsinki, Finland
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